{"id":2080,"date":"2008-02-16T08:01:10","date_gmt":"2008-02-16T12:01:10","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=2080"},"modified":"2008-02-16T08:01:10","modified_gmt":"2008-02-16T12:01:10","slug":"fda-issues-an-early-communication-about-an-ongoing-safety-review-for-botox-and-botox-cosmetic","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/2080","title":{"rendered":"FDA issues an Early Communication about an Ongoing Safety Review for Botox and Botox Cosmetic"},"content":{"rendered":"<p><strong>FDA issues an Early Communication about an Ongoing Safety Review for Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)<\/strong><\/p>\n<p><em>This information reflects FDA&#39;s current analysis of available data concerning these drugs. Posting this information does not mean that FDA has concluded there is a causal relationship between the drug products and the emerging safety issue.&nbsp; Nor does it mean that FDA is advising healthcare professionals to discontinue prescribing these products. FDA is considering, but has not reached a conclusion about whether this information warrants any regulatory action. FDA intends to update this document when additional information or analyses become available.<\/em><\/p>\n<p><!--more--><\/p>\n<p>&nbsp;Descargue art\u00edculo completo:<\/p>\n<p><a href=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/2007\/12\/187\/fda-issues-an-early-communication-about-an-ongoing-safety-review-for-botox.doc\" title=\"fda-issues-an-early-communication-about-an-ongoing-safety-review-for-botox.doc\">fda-communication-about-botox.doc<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA issues an Early Communication about an Ongoing Safety Review for Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) This information reflects FDA&#39;s current analysis of available data concerning these drugs. Posting this information does not mean that FDA has concluded there is a causal relationship between the drug &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-2080","post","type-post","status-publish","format-standard","","category-farmacologia"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/2080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=2080"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/2080\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=2080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=2080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=2080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}